)
Jane Seagal
Vice President, Antibody Discovery,
Ablexis and AlivaMab Biologics
Jane has over a decade of experience in antibody drug discovery using in vivo approaches. Prior to joining AlivaMab Biologics, Jane led the In Vivo Antibody Discovery team at AbbVie, where she introduced and implemented multiple technology platforms, including hybridoma automation and direct antibody cloning from human patient samples. Jane has led projects across diverse therapeutic areas and enabled antibody discovery campaigns resulting in several clinical candidate molecules
Sessions
-
23-Sep-2024TOPIC TBC by Alivamab
-
17-Jun-2024Salon HOpening Address & Keynote Presentation by Ablexis and AlivaMab Biologics. Driven by Diversity: AlivaMab' Platforms Fuel Biologics Discovery for Complex Targets
-
17-Jun-2024Salon DTechnologies accelerating engineering into advanced modalities
-
17-Jun-2024Salon CPoster Presentation: AlivaMab' Platforms for Discovery and Engineering for Bispecifics and Advanced Modalities Jane Seagal, Vice President, Antibody Discovery, Ablexis and AlivaMab Discovery Services [Bi/ Multi Specifics Topic]